



Contacts: Bret L. Udem
Media Relations
Tel. (425) 493-2293
Fax. (425) 493-2010

FOR RELEASE
April 10, 2006

CombiMatrix Molecular Diagnostics Establishes A Facility In The State-Of-The-Art MaRS Discovery District in Toronto, Ontario, Canada

Newport Beach, Calif. – (BUSINESS WIRE) – April 10, 2006 – Acacia Research Corporation (Nasdaq: CBMX:ACTG) announced today that its CombiMatrix group's wholly-owned subsidiary CombiMatrix Molecular Diagnostics (CMDX) has established a new facility in the world-class MaRS Discovery District in downtown Toronto.

“With the abundance of stellar scientists and research and clinical activities in and around the MaRS discovery district and the fact that our Chief Scientific Officer and Vice President, Dr. Mansoor Mohammed, is a Canadian citizen, it was an easy and obvious choice for our expansion into the Canadian arena,” said Dr. Amit Kumar, CEO of CombiMatrix. “Moving forward we anticipate establishing strong relationships with Canadian customers, partners and the government.”

“Ontario's highly-skilled workforce, leading-edge research and proven ability to discover new ideas and turn them into innovative products is helping build a pervasive culture of innovation in our province,” said Premier and Minister of Research and Innovation, Dalton McGuinty. “The MaRS Discovery District supports the discovery, funding and marketing of new ideas all in the same building. With its strong reputation for leading-edge research, CMDX is a welcome addition to this world-class facility.”

Dr. Mohammed has been at the forefront of research and development in the fields of Comparative Genomic Hybridization (CGH) and microarray technologies for his entire professional career. Between 2001 and 2003 he produced the world's first commercially viable whole genome BAC array and co-authored one of its seminal clinical applications. He later directed the Advanced Technologies and Genomics program at Quest Diagnostics Inc, North America's largest commercial clinical laboratory. He is an internationally renowned scientist, speaker, and author and holds multiple patents in the fields of clinical genomics and microarray technology. “We are delighted to welcome Dr. Mohammed and CMDX to the MaRS Discovery District,” said Dr. Ilse Treurnicht, MaRS CEO. “MaRS is dedicated to building a global gateway to Ontario research and innovation, and attracting world-class companies like CMDX is a critical component of our strategy.”

“Toronto's vibrant medical and research institutions have long since demonstrated a strong track record for clinical trials initiatives with several of the world's leading pharmaceutical entities”, added Dr. Mohammed, Chief Scientific Officer and Vice President of CMDX. “By placing our transformative genomic microarray technologies at the very epicenter of these

activities, we anticipate creating a one-of-a-kind fusion between pharmacogenomic pursuits and genomics-based diagnostics. I am very excited to be involved in this expansion of CMDX and I am particularly proud to see its manifestation in Toronto. We anticipate drawing heavily from the exceptionally well-qualified researchers trained within the greater Toronto medical research community and I am eager to see to fruition the commercialization of novel, high value gene-based diagnostic products and services that I am certain will follow from our Canadian activities.”

ABOUT MaRS

MaRS Discovery District (www.marsdd.com) is a not-for-profit corporation founded by leaders from the business and public sectors, to improve commercial outcomes from Canada’s foundation of science and technology innovation. MaRS connects and fosters collaboration between the communities of science, business and capital through co-location in the MaRS Centre and more broadly through catalytic programs, structured networks and the MaRS web portal.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT[®]), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (NASDAQ: ACTG) and Acacia Research-CombiMatrix (NASDAQ: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based

upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.